The latest price target for Bellicum Pharmaceuticals Inc (OTC:BLCM) was reported by Ladenburg Thalmann on February 16, 2022. The analyst firm set a price target for $5.00 expecting BLCM to rise to within 12 months (a possible 6588.96% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellicum Pharmaceuticals Inc (OTC:BLCM) was provided by Ladenburg Thalmann, and Bellicum Pharmaceuticals Inc initiated their buy rating.

There is no last upgrade for Bellicum Pharmaceuticals Inc

There is no last downgrade for Bellicum Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellicum Pharmaceuticals Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellicum Pharmaceuticals Inc was filed on February 16, 2022 so you should expect the next rating to be made available sometime around February 16, 2023.

While ratings are subjective and will change, the latest Bellicum Pharmaceuticals Inc (BLCM) rating was a initiated with a price target of $0.00 to $5.00. The current price Bellicum Pharmaceuticals Inc (BLCM) is trading at is $0.07, which is within the analyst’s predicted range.